Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome
Matthew L. Hemming(University of Massachusetts Chan Medical School), James E. Bradner(Novartis (China)), Matthew A. Lawlor(Dana-Farber Cancer Institute), Tom Lesluyes(Université de Bordeaux), Ewa Sicińska(Harvard University), Frédéric Chibon(Centre National de la Recherche Scientifique), Chandrajit P. Raut(Dana-Farber Cancer Institute), George D. Demetri(Dana-Farber Cancer Institute), Rhamy Zeid(C4 Therapeutics (United States)), Jonathan A. Fletcher(Harvard University), Scott A. Armstrong(Courant Institute of Mathematical Sciences)
Cited by 43
Related Papers
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k